# Rituximab and Belimumab for Lupus Nephritis

> **NCT02260934** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 43 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone
- **DRUG:** Methylprednisolone
- **DRUG:** Diphenhydramine
- **DRUG:** Acetaminophen
- **BIOLOGICAL:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone
- **DRUG:** Methylprednisolone
- **DRUG:** Diphenhydramine
- **DRUG:** Acetaminophen
- **BIOLOGICAL:** Belimumab

## Key facts

- **NCT ID:** NCT02260934
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-09
- **Primary completion:** 2018-03-12
- **Final completion:** 2019-02-08
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260934, "Rituximab and Belimumab for Lupus Nephritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02260934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*